Scrip is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Quick Listen: Scrip's Five Must-Know Things

Executive Summary

In this week's podcast edition of Five Must-Know Things: Biomarin’s next chapter; Amgen’s obesity plans; Daiichi’s new ADC data; Acelyrin hit by clinical failure; and Skyrizi beats Stelara in Crohn’s.

Join us for an audio catch-up on the major events in the biopharma industry over the past business week, as reported by Scrip's global team, in this podcast version of Five Must-Know Things.

This episode covers insights for the business week ended 15 September 2023, including: BioMarin Pharmaceutical Inc.’s next chapter; Amgen, Inc.’s obesity plans; Daiichi Sankyo Co., Ltd.’s new ADC data; Acelyrin, Inc. hit by clinical failure; and Skyrizi beats Stelara in Crohn’s.

This and all our other podcasts are available on the Pharma Intelligence channel on Apple PodcastsGoogle PodcastsSoundCloudTuneIn and Spotify Podcasts, and via smart speakers if one of these platforms has been set up as your default podcast provider.  

Stories mentioned in this episode: 

(Also see "BioMarin’s Next Chapter: ‘A Financial Growth Story’" - Scrip, 13 Sep, 2023.)

(Also see "Amgen’s Plan To Go Big In Obesity" - Scrip, 12 Sep, 2023.)

(Also see "Daiichi Sankyo Comes Out Swinging At WCLC As ADCs Steal Show" - Scrip, 11 Sep, 2023.)

(Also see "Acelyrin Goes From Float To Sink" - Scrip, 12 Sep, 2023.)

(Also see "AbbVie’s Skyrizi Bests Stelara Head-To-Head In Crohn’s" - Scrip, 12 Sep, 2023.)



Related Content


Related Companies

Latest Headlines
See All



Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Thank you for submitting your question. We will respond to you within 2 business days. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts